The development of monoclonal antibodies against PD1 (pembrolizumab and nivolumab), PDL1 (atezolizumab, durvalumab and avelumab) and CTLA4 (ipilimumab) has created a new paradigm in the treatment of cancers by directly targeting immune cells, to stimulate an antitumor response, and not only cancer cells. Here, CTLA4 is linked to cancer.